When was Regulus Therapeutics founded?

Regulus Therapeutics was founded in 2007 and raised its 1st funding round 2 years after it was founded.

Where is Regulus Therapeutics located?

Regulus Therapeutics is headquartered in San Diego, United States. It is registered at Woodstock, Virginia.

How many employees does Regulus Therapeutics have?

As of Mar 01, 2026, the latest employee count at Regulus Therapeutics is 10 - 49.

Is Regulus Therapeutics a funded company?

Regulus Therapeutics is a funded company, having raised a total of $35M across 11 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 03, 2009.

How much is Regulus Therapeutics worth?

The last known valuation of Regulus Therapeutics was $***** as of Apr 30, 2025.

When was the latest funding round of Regulus Therapeutics?

Regulus Therapeutics' latest funding was a $***** Post IPO round on Mar 12, 2024, with participation from 7 investors.

What is the annual revenue of Regulus Therapeutics?

Annual revenue of Regulus Therapeutics is between $10M and $50M as on Dec 31, 2020

Where does Regulus Therapeutics rank among its competitors?

Regulus Therapeutics ranks 80th amongst 385 active competitors, of which 130 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was GenSight Biologics, which secured $1.96M in Mar, 2026.

Who are the top competitors of Regulus Therapeutics?

Regulus Therapeutics' top competitors include MedGenome, Geneoscopy and Ionis. Among them, GenSight Biologics secured the most recent funding round in March, 2026.

Regulus Therapeutics - 2026 Company Profile, Funding & Competitors

Company Details

Innovative medicines company reimagining medicine to improve and extend people’s lives. Focused on addressing society’s greatest disease burdens, it develops transformative, high-value treatments across various therapeutic areas, including cardiovascular, renal, metabolic, immunology, neuroscience, and oncology. The company embraces breakthrough science and new technologies to fight disease and improve patient outcomes. Committed to environmental, social, and governance (ESG) principles, it strives to make a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. The company fosters a culture of inclusion, promoting diversity and belonging among its people. It also supports global health initiatives, including pandemic preparedness and disease elimination programs. The company engages in research and development, collaborations, and partnerships to discover and deliver innovative solutions for patients worldwide.

Website: regulusrx.com
Social
Registered Address: Woodstock, Virginia

Key Metrics

Founded Year

2007

Location

San Diego, United States

Stage

Acquired

Total Funding

$35M in 11 rounds

Latest Funding Round

Post IPO, Mar 12, 2024, $*****

Last Known Valuation

$***** as on Apr 30, 2025

Investors

Alnylam & 9 more

Ranked

80^th among 385 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2020

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

MedGenome & 541 more

Exit Details

Acquired by Novartis (Apr 30, 2025)

View Regulus Therapeutics' full profile

Regulus Therapeutics is associated with 5 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Regulus Therapeutics Inc. CIN: 1505512 , United States, Active		$10M - $50M (As on Dec 31, 2020)	-	-
Regulus Therapeutics Inc CIN: 20228212903 , United States, Active	Dec 13, 2022	-	-	-
Regulus CIN: 40103251399 , Latvia, Active	Oct 01, 2009	€0 - €1M (As on Dec 31, 2020)	1 (As on Dec 31, 2020)	-
Regulus Therapeutics Inc. CIN: 264738379 , United States, Active	Dec 31, 2006	$10M - $50M (As on Dec 31, 2020)	30 (As on Dec 31, 2023)	-
REGULUS CIN: 331009928 , United States, Active	Dec 31, 1999	-	241 (As on Dec 31, 2024)	-

Regulus Therapeutics got acquired by Novartis on Apr 30, 2025 at an acquisition amount of $*****.

Click here to take a look at Regulus Therapeutics's acquisition in detail

Regulus Therapeutics has raised a total funding of $35M over 11 rounds. Its first funding round was on Mar 03, 2009. Its latest funding round was a Post IPO round on Mar 12, 2024 for $*****. 7 investors participated in its latest round. Regulus Therapeutics has 10 institutional investors.

Here is the list of recent funding rounds of Regulus Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 12, 2024	5666626	Post IPO	3640365	6295506	3692250	5935939
Apr 13, 2023	7233544	Post IPO	5919450	1761388	6300277	New Enterprise Associates & 1 more
Nov 24, 2021	9886978	Post IPO	7409426	5310086	8716423	New Enterprise Associates & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Regulus Therapeutics's funding rounds and investors

Regulus Therapeutics' employee count trend

Regulus Therapeutics has 10 - 49 employees as of Mar 26. Here is Regulus Therapeutics's employee count trend over the years:

Employee count trend for Regulus Therapeutics

Uncover Regulus Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Regulus Therapeutics include MedGenome, Geneoscopy and Ionis. Here is the list of Top 10 competitors of Regulus Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MedGenome 2013, Bengaluru (India), Series E	Provider of DNA sequencing, bioinformatics, and multiomics services	$264M	Novo Holdings, Peak XV Partners & 30 others	70/100
2nd	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
3rd	Ionis 1989, United States, Public	Developer of RNA-targeted medicines for various diseases	-	BB Biotech, Ojp & 1 others	67/100
4th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	66/100
5th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Atlas Venture, Novartis & 10 others	66/100
6th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, True Ventures & 16 others	62/100
7th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Gilde Healthcare, Advent Life Sciences & 11 others	62/100
8th	ProQR Therapeutics 2012, Leiden (Netherlands), Public	Developer of RNA-based therapeutics for the treatment of genetic disorders such as inherited retinal disorders	$58M	Sofinnova Partners, Gilde Healthcare & 7 others	61/100
9th	GenSight Biologics 2011, Paris (France), Public	Developer of viral vector-based gene therapies for retinal neurodegenerative diseases	$76.6M	Perceptive Advisors, Fidelity Investments ... & 17 others	61/100
10th	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Mayo Clinic Business Accelerator ... & 8 others	60/100
80th	Regulus Therapeutics 2007, San Diego (United States), Acquired	Innovative medicines company reimagining medicine to improve and extend people’s lives	$35M	Foresite Capital, RA Capital Management & 8 others	62/100